Search Results for keywords:"section 529 FD

The Federal Bureau of Investigation (FBI)'s Criminal Justice Information Services (CJIS) Division announced its intent to submit a request for an information collection regarding the FBI Expungement and Sealing Form (FD-1114) to the Office of Management and Budget (OMB). This request is intended to ensure information accuracy within the FBI's systems and is required by federal regulations. The public has until April 28, 2025, to provide comments on the proposed collection. The information collection targets state, local, tribal, and federal governments, with an estimated 147,610 respondents and a total annual burden of 8,611 hours.

The Justice Department's Criminal Justice Information Services (CJIS) Division is seeking public comments on a proposed information collection activity. This involves the FBI Records Modification Form (FD-1115), which helps ensure criminal history information is accurately managed in compliance with privacy regulations. The form is necessary for state, local, Tribal, and Federal governments to edit their records accurately since manual updates may be required. Comments will be accepted until March 17, 2025, and focus on the necessity, accuracy, enhancement, and minimization of respondent burden related to the information collection.

The Federal Bureau of Investigation's (FBI) Criminal Justice Information Services (CJIS) Division, part of the Department of Justice (DOJ), has announced a proposal to revise a previously approved information collection, specifically the FBI Expungement and Sealing Form (FD-1114). This notice, in compliance with the Paperwork Reduction Act, invites public comments on the necessity, accuracy, and enhancement of the information collection, which is mandatory for state, local, tribal, and federal agencies. The collection aims to ensure accurate and secure identity history records in systems like the National Crime Information Center. The estimated annual response rate for this form is 147,610, with each response taking approximately 3.5 minutes, totaling an annual burden of 8,611 hours. Comments will be accepted until March 10, 2025.

The Office of the Secretary of the Defense Department issued a correction regarding a previously published notice in the Federal Register. The notice, originally published on January 6, 2021, had an incorrect date listed in its DATES section. The date “April 1, 2021” was corrected to “March 8, 2021” on page 529. This update ensures that anyone referencing the document has the accurate timeline information.

The Internal Revenue Service (IRS) is requesting comments on the information collection concerning Form 1099-Q, which relates to payments from qualified education programs under sections 529 and 530 of the Internal Revenue Code. This effort aims to reduce paperwork and burden on respondents, adhering to the Paperwork Reduction Act of 1995. The IRS invites feedback on various aspects, such as the necessity and utility of the information collected, ways to minimize respondent burden, and the overall effectiveness of the collection process. Comments must be submitted by March 23, 2021, to be considered.

The Food and Drug Administration (FDA) has decided to revoke the use of the color additive FD&C Red No. 3 in foods and ingested drugs. This decision was based on evidence showing that FD&C Red No. 3 can cause cancer in male rats, which under the law, makes it unsafe. Although the risk to humans is considered low, the FDA is compelled by law to remove this additive because it has been linked to cancer in animals. The order will take effect on January 15, 2027, but objections can be submitted until February 18, 2025, if anyone is adversely affected by this ruling.

The Food and Drug Administration (FDA) has issued an order under the Federal Food, Drug, and Cosmetic Act to permanently ban Sunrise Lee from working with any person or company that has a drug product application. This decision follows her felony conviction for racketeering related to the regulation of a drug product. Lee, who previously worked in a leadership role at Insys Therapeutics, was found guilty of participating in a conspiracy to bribe medical practitioners to prescribe a fentanyl-based drug called SUBSYS. Despite being notified of the proposed ban and given a chance to contest it, Lee did not respond, resulting in a waiver of her right to a hearing.

The Food and Drug Administration (FDA) is issuing a permanent debarment order against Joseph A. Rowan, preventing him from working with any businesses that have drug product applications. This order results from Mr. Rowan's felony conviction related to illegal activities with the drug SUBSYS while at Insys Therapeutics. He was found guilty of racketeering, mail fraud, and wire fraud, including bribing doctors to prescribe SUBSYS to patients without cancer and misleading insurers. Mr. Rowan was notified of this debarment decision and waived his right to contest it by not requesting a hearing.

The Food and Drug Administration (FDA) has issued an order permanently banning Jerrod Nichols Smith from providing services related to drug product applications. This decision follows his conviction on multiple felony counts of mail fraud and obstruction of justice, connected with the unlawful distribution and misrepresentation of prescription drugs. Smith's company, Cumberland Distribution, was involved in distributing drugs illegally obtained from unlicensed sources, leading to significant profit from falsified documents and drug mislabeling. After being notified, Smith did not respond or request a hearing, resulting in his debarment which prohibits him from engaging in drug product services.

The Food and Drug Administration (FDA) issued a permanent debarment order against Alec Burlakoff under the Federal Food, Drug, and Cosmetic Act. Burlakoff was convicted of a felony involving illegal activities with a drug called SUBSYS while working at Insys Therapeutics. His actions included bribing doctors to prescribe the drug, often to patients who did not have cancer. As a result, Burlakoff is banned from providing services related to drug product applications, and there are penalties for any approved drug product applications that employ him during this period.